UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

Lingvay, I; Brown-Frandsen, K; Colhoun, HM; Deanfield, J; Emerson, SS; Esbjerg, S; Hardt-Lindberg, S; ... Ryan, DH; + view all (2023) Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity , 31 (1) pp. 111-122. 10.1002/oby.23621. Green open access

[thumbnail of Semaglutide for cardiovascular event reduction.pdf]
Preview
PDF
Semaglutide for cardiovascular event reduction.pdf - Published Version

Download (1MB) | Preview

Abstract

Objective: This paper describes the baseline characteristics of the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) study, one of the largest cardiovascular (CV) outcome studies in the field of obesity, which evaluates the effect of semaglutide versus placebo on major CV events. Methods: SELECT enrolled individuals with overweight or obesity without diabetes, with prior myocardial infarction, stroke, and/or peripheral artery disease. This study reports participants' baseline characteristics in the full study population and subgroups defined by baseline glycated hemoglobin (HbA1c; <5.7%, ≥5.7 to <6.0%, ≥6.0 to <6.5%), baseline waist to height ratio tertile, and qualifying prior CV event or condition. Results: The study enrolled 17,605 participants (72.5% male) with an average (SD) age of 61.6 (8.9) years and BMI of 33.34 (5.04) kg/m2. The most common prior CV event was myocardial infarction (76.3% of participants), followed by stroke (23.3%) and peripheral artery disease (8.6%). Furthermore, 24.3% had a heart failure diagnosis. Two-thirds of participants (66%) had HbA1c in the prediabetes range (5.7%-6.4%). Across groups of increasing HbA1c, prevalence of all CV risk factors increased. Conclusions: The enrolled population in SELECT includes participants across a broad range of relevant risk categories. This will allow the study to garner information about the CV benefits of semaglutide across these relevant clinical subgroups.

Type: Article
Title: Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/oby.23621
Publisher version: https://doi.org/10.1002/oby.23621
Language: English
Additional information: © 2022 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Keywords: Female, Humans, Male, Middle Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Myocardial Infarction, Obesity, Overweight, Peripheral Arterial Disease, Stroke
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Clinical Science
URI: https://discovery.ucl.ac.uk/id/eprint/10162471
Downloads since deposit
1,221Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item